|

QEL-005 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Quell Therapeutics Limited1

Indications

  • Diffuse Cutaneous Systemic Sclerosis1
  • Rheumatoid Arthritis (RA1
  • Autoimmune Rheumatologic Disease1
  • Systemic Sclerosis (SSc)1
  • Arthritis1

Other1 trial

Controlling Hyperactive Immunity With Long-lived Lymphocytes
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.